Alder Biopharm (ALDR) Weakness Creates Buying Opportunity - Jefferies

November 17, 2016 7:58 AM EST
Get Alerts ALDR Hot Sheet
Price: $21.35 --0%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade ALDR Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst Brian Abrahams said weakness in Alder Biopharm (NASDAQ: ALDR) following study data creates a buying opportunity. The firm reiterated a Buy rating and price target of $57.

Abrahams commented, "New data from AMGN's second registrational study showed consistent (and if anything, improved) efficacy in migraine reductions without any safety signals-- reaffirming the potential of the CGRP mAb class and further de-risking the potential for success of ALDR's eptinezumab (ALD403). Continue to view '403's promise and oppty as significantly underappreciated in ALDR shares and see a particularly attractive buying oppty after today's weakness."

For an analyst ratings summary and ratings history on Alder Biopharm click here. For more ratings news on Alder Biopharm click here.

Shares of Alder Biopharm closed at $29.58 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Jefferies & Co

Add Your Comment